Snapshot · The Diary Of A CEO with Steven Bartlett
People who reported higher life purpose before death had greater mitochondrial energy transformation capacity in the dorsolateral prefrontal cortex — the brain region governing executive function.
Where this was said
At 1:47:40 · chapter starts 1:46:35
Bartlett mentions he read that brains of deceased people with greater purpose had more efficient mitochondria — and Picard describes the study in detail. Participants in Chicago reported their sense of purpose, optimism, and social connection annually before death; after death, researchers measured mitochondrial energy transformation capacity in the dorsolateral prefrontal cortex. Those who felt more purpose had lower energy resistance in their brain's executive-function region. The causality, Picard explains, runs in both directions — confirmed by animal experiments where stressing mice changes their brain mitochondria, and where directly boosting or suppressing brain mitochondria changes anxiety, sociality, and dominance. If your mitochondria are healthy, you experience life as more meaningful. If life feels meaningful, your mitochondria work better. The practical implication: losing purpose — from burnout, isolation, or chronic stress — causes measurable mitochondrial decline that shows up as fatigue, pessimism, and what we label depression.
A long-running Chicago study asked people annually about purpose and meaning, then examined their brains after death. Those who reported greater life purpose had higher mitochondrial energy transformation capacity in the dorsolateral prefrontal cortex — and crucially, mouse studies show the relationship runs both ways.
Animals first sensed light 540 million years ago, triggering an evolutionary acceleration known as the Cambrian explosion within 10 million years.
It is estimated that half of all cortical activity in the human brain is involved in visual function, underscoring vision's central role in intelligence.
Cognitive neuroscience literature shows that by age 6, humans can recognize tens of thousands of different object categories — far more data than early AI systems were trained on.
Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, making an unknown mechanism a meaningful early red flag for any compound.
Even compounds that clear preclinical testing often fail in humans: 30 to 50% of drugs entering phase 1 trials do not advance to phase 2, frequently because human behavior differs from animal models.
More than 80% of published BPC-157 research comes from a single academic group whose researchers have IP and commercial interests connected to the molecule, limiting independent replication.
Roughly 100 peptide drugs are already FDA-approved, about 150 more are in clinical trials, and 600–700 are in preclinical development, underscoring the legitimacy of peptide science broadly.
The scientist who discovered BPC-157 refused to disclose the screening method used to identify the compound and has never fully published the parent protein sequence — what Peter Attia calls 'scientific trust me, bro.'
The brain's visual, auditory, and motor cortices light up nearly identically whether an experience is real or imagined, making visualization a form of actual neural training.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.